Overall management of patients with Dravet syndrome

Dev Med Child Neurol. 2011 Apr:53 Suppl 2:19-23. doi: 10.1111/j.1469-8749.2011.03968.x.

Abstract

Dravet syndrome, or as it was called in the past 'severe myoclonic epilepsy in infancy', is a drug-resistant epilepsy first described by Charlotte Dravet in 1978. Besides the well-known and well-described therapy resistance, Dravet syndrome dramatically impacts the development and behaviour of the affected children. As it is still not a curable disease, families need to be taught how to cope with the disorder and will require assistance from both clinical and non-clinical structures. At the onset of the disease, many questions arise regarding the diagnosis of Dravet syndrome, the severity of the illness and its deleterious effects, and the management of seizures, especially the long-lasting status epilepticus. Once the diagnosis has been established, severe convulsions, often unpredictable and long-lasting, are still a major worry, but developmental and behavioural problems also rapidly become a serious concern. Later on, nearly all parents will have a child who becomes an adult with special needs, requiring specialised attention from professionals.

Publication types

  • Review

MeSH terms

  • Adult
  • Caregivers / psychology*
  • Child Development
  • Child, Preschool
  • Epilepsies, Myoclonic / nursing*
  • Epilepsies, Myoclonic / psychology
  • Epilepsies, Myoclonic / therapy
  • Family Health
  • Humans
  • Infant
  • Syndrome
  • Young Adult